---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000097"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:35:19.520801+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity

## Summary
- Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.
- Anaptys has repurchased 3,443,188 shares (11.2% of shares outstanding) under the plan to date.
- Company expects ~$300M cash end-2025, including anticipated $75M commercial milestone from GSK on Jemperli reaching $1B sales.
- Plan expires March 31, 2026; repurchases depend on market conditions and regulatory limitations.

## SEC filing metadata
- accession: 0001370053-25-000097
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/0001370053-25-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/anab-20251121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000097
- JSON: https://secwatch.observer/filing/0001370053-25-000097.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.